文献速递炎症性肠病

炎症性肠病药物基因组学护照的预测效能

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-03

本研究回顾性评估710例暴露于硫嘌呤和/或TNFα拮抗剂的IBD患者,利用全外显子测序和芯片基因分型构建预测硫嘌呤毒性和TNFα拮抗剂免疫原性的药物基因组学护照。护照可预测54例(36%)药物不良反应,需基因分型24例以预防1例不良反应,支持其临床实施。

要点

  • 药物基因组学护照可预测36%的硫嘌呤毒性或TNFα拮抗剂免疫原性。
  • 每预防1例药物不良反应需基因分型24例患者。
  • 将护照纳入临床管理可能减少IBD药物不良反应。

核心结论

  • 药物基因组学护照对IBD药物不良反应具有临床效能,实施可能减少不良反应。

研究设计与样本

  • 回顾性评估710例暴露于硫嘌呤和/或TNFα拮抗剂的IBD患者,使用全外显子测序和Illumina Global Screening Array进行基因分型。

主要发现

  • 710例患者中发生150例药物不良反应,护照预测了其中54例(36%)。

关键数值与推荐

  • 每预防1例药物不良反应需基因分型24例患者。

临床怎么用

  • 对计划使用硫嘌呤或TNFα拮抗剂的IBD患者,可考虑药物基因组学护照指导治疗以降低不良反应风险。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High inter-individual variability in therapeutic response to drugs used in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and high costs. Genetic variants predictive of thiopurine-induced myelosuppression, thiopurine-induced pancreatitis and immunogenicity of Tumour Necrosis Factor alpha (TNFα) antagonists have been identified, but uptake of pre-treatment pharmacogenetic testing into clinical guidelines has been slow. AIM: To explore the efficacy of a pharmacogenetic passport for IBD that includes multiple pharmacogenetic predictors of response. METHODS: Patients with IBD exposed to thiopurines and/or TNFα antagonists were retrospectively evaluated for the presence of thiopurine toxicity and/or immunogenicity of TNFα antagonists. All patients were genotyped using both whole-exome sequencing and the Illumina Global Screening Array. An in-house-developed computational pipeline translated genetic data into an IBD pharmacogenetic passport that predicted risks for thiopurine toxicity and immunogenicity of TNFα antagonists per patient. Using pharmacogenetic-guided treatment guidelines, we calculated clinical efficacy estimates for pharmacogenetic testing for IBD. RESULTS: Among 710 patients with IBD exposed to thiopurines and/or TNFα antagonists, 150 adverse drug responses occurred and our pharmacogenetic passport would have predicted 54 (36%) of these. Using a pharmacogenetic passport for IBD that includes genetic variants predictive of thiopurine-induced myelosuppression, thiopurine-induced pancreatitis, and immunogenicity of TNFα antagonists, 24 patients need to be genotyped to prevent one of these adverse drug responses. CONCLUSIONS: This study highlights the clinical efficacy of a pharmacogenetic passport for IBD. Implementation of such a pharmacogenetic passport into clinical management of IBD may contribute to a reduction in adverse drug responses.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bangma A, Voskuil MD, Uniken Venema WTC, et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32363635. doi:10.1111/apt.15762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。